Acadia soars on successful schizophrenia drug trial

Shares of San Diego-based Acadia Pharmaceuticals soared 87 percent this morning after researchers announced that the biotech's schizophrenia drug, ACP-103, hit its goal in a mid-stage trial. The trial tested ACP-103 in combination with the generic haloperidol and risperidone.

"These data clearly demonstrate the advantages of co-therapy with ACP-103 and show the importance of 5-HT2A receptor antagonism in schizophrenia therapy," said Herbert Y. Meltzer, M.D., professor of psychiatry and pharmacology at Vanderbilt University School of Medicine. "Current antipsychotic agents used to treat schizophrenia and related neuropsychiatric disorders have many dose-related limitations. The use of ACP-103 in co-therapy with risperidone or other modern atypical antipsychotics may result in enhanced efficacy and an improved side effect profile, suggesting a formula for a new and improved treatment paradigm for patients with schizophrenia."

- check out the release for more information
- here's the AP's report on the trial

Related Articles:
Acadia drug flunks primary endpoint in mid-stage trial. Report
Acadia touts positive sleep study data. Report

Suggested Articles

The money will support work on a biologic drug cocktail that Lumen thinks can be a scalable, inexpensive fix for gastrointestinal symptoms.

The readouts link the oral oxidative phosphorylation blocker imeglimin to near- and long-term improvements when given as a monotherapy and in combos.

Scientists at the University of Toronto, in collaboration with Agios, identified 182 genes that allow cancer cells to evade the immune system.